Corient Private Wealth LP acquired a new stake in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 27,415 shares of the company's stock, valued at approximately $2,476,000.
A number of other large investors also recently modified their holdings of the company. Acumen Wealth Advisors LLC bought a new position in HealthEquity in the 4th quarter valued at about $27,000. Aster Capital Management DIFC Ltd purchased a new stake in HealthEquity in the 4th quarter valued at $28,000. Caitong International Asset Management Co. Ltd lifted its stake in HealthEquity by 1,723.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company's stock valued at $28,000 after acquiring an additional 293 shares in the last quarter. Leonteq Securities AG lifted its stake in HealthEquity by 159.9% during the 1st quarter. Leonteq Securities AG now owns 382 shares of the company's stock valued at $32,000 after acquiring an additional 235 shares in the last quarter. Finally, Silvant Capital Management LLC purchased a new position in HealthEquity during the 2nd quarter worth $35,000. 99.55% of the stock is currently owned by institutional investors.
HealthEquity Stock Performance
Shares of HQY stock opened at $98.54 on Thursday. The stock has a market capitalization of $8.15 billion, a P/E ratio of 35.57, a PEG ratio of 1.53 and a beta of 0.22. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.47. The firm's 50 day moving average is $98.91 and its 200 day moving average is $88.38. HealthEquity, Inc. has a 12 month low of $72.76 and a 12 month high of $107.62.
HealthEquity (NASDAQ:HQY - Get Free Report) last released its quarterly earnings data on Thursday, August 27th. The company reported $1.24 earnings per share for the quarter, beating analysts' consensus estimates of $1.19 by $0.05. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. The business had revenue of $350.73 million during the quarter, compared to analyst estimates of $349.22 million. The firm's quarterly revenue was up 95.5% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. On average, sell-side analysts anticipate that HealthEquity, Inc. will post 3.93 earnings per share for the current year.
Insiders Place Their Bets
In other news, Director Adrian T. Dillon sold 7,632 shares of the firm's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total value of $798,383.52. Following the completion of the transaction, the director directly owned 62,395 shares of the company's stock, valued at $6,527,140.95. This trade represents a 10.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Henry Fiore sold 2,470 shares of HealthEquity stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $95.00, for a total value of $234,650.00. Following the completion of the transaction, the executive vice president owned 56,643 shares of the company's stock, valued at approximately $5,381,085. This trade represents a 4.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 12,456 shares of company stock valued at $1,256,664 over the last ninety days. Corporate insiders own 1.60% of the company's stock.
Analyst Ratings Changes
Several research firms have recently issued reports on HQY. KeyCorp reiterated an "overweight" rating on shares of HealthEquity in a research note on Tuesday, May 26th. Weiss Ratings upgraded shares of HealthEquity from a "hold (c)" rating to a "hold (c+)" rating in a report on Friday, June 5th. Barrington Research restated an "outperform" rating and set a $110.00 price target on shares of HealthEquity in a report on Friday, May 22nd. Wells Fargo & Company set a $111.00 price objective on shares of HealthEquity in a research report on Monday, June 1st. Finally, Royal Bank Of Canada increased their price target on HealthEquity from $100.00 to $108.00 and gave the company an "outperform" rating in a research report on Wednesday, June 3rd. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, HealthEquity currently has an average rating of "Moderate Buy" and a consensus target price of $111.87.
Read Our Latest Stock Report on HQY
HealthEquity Profile
(
Free Report)
HealthEquity, Inc NASDAQ: HQY is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.
Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.